Natera Inc. Update: Recent Price Movement and Key Milestones

Natera Inc., a diagnostic company operating in the health care sector with a focus on biotechnology, has recently made headlines with its presentation at ESMO GI. The company showcased the clinical and economic utility of its Signatera product, a key offering in its portfolio of genetic testing services. Natera provides a range of services including preconception and prenatal genetic testing, pre-implantation genetic diagnosis, aneuploidy screening, translocation, and single gene testing. These services cater to customers primarily in the United States.

The company’s stock has experienced notable fluctuations over the past year, with a 52-week range between $92.14 and $183. As of July 6, 2025, the close price was recorded at $158.69, indicating moderate volatility. The last recorded close price before this was $161.76, reflecting ongoing investor interest and market dynamics.

Natera Inc. went public on Nasdaq on July 2nd, 2015, and continues to be a significant player in the biotechnology industry. The company’s focus on innovative genetic testing solutions positions it well within the health care sector, as it addresses critical needs in genetic diagnostics. For more information, Natera can be accessed through their website at www.natera.com .